HOME-USE PROTHROMBIN DIAGNOSTICS WOULD REQUIRE CLINICAL TRIALS
This article was originally published in The Tan Sheet
Executive Summary
HOME-USE PROTHROMBIN DIAGNOSTICS WOULD REQUIRE CLINICAL TRIALS at a minimum of three sites studying normal patients and patients with "different hematologic profiles," Djuana Blagmon of FDA's Division of Clinical Laboratory Devices told an Aug. 5 meeting of the agency's Hematology and Pathology Devices Advisory Panel. The panel discussed the feasibility, safety and effectiveness of home- use prothrombin time tests. The tests are currently used only in professional settings, but FDAers said manufacturers have expressed interest in marketing home-use versions and have inquired about FDA's submission policy.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning